Small Cell Lung Cancer
The addition of pravastatin to first-line chemotherapy did not improve overall survival or progression-free survival in patients with small-cell lung cancer.
The addition of bevacizumab to first-line treatment with cisplatin plus etoposide improved PFS, but not OS, with an acceptable toxicity profile in patients with extensive-disease SCLC.
Continued adoption of stereotactic body radiation therapy (SBRT) to treat early stage NSCLC improved OS and lung cancer-specific survival, according to a study presented at the 2016 annual meeting of the American Society for Radiation Oncology.
The addition of vandetanib to a platinum agent and etoposide did not improve time to progression or overall survival in patients with newly diagnosed extensive-stage SCLC.
Surgery for early stage small cell lung cancer (SCLC) is rarely used. However, results from a population-based database has shown surgery with adjuvant chemotherapy with or without radiation for node-negative SCLC was associated with better survival compared with concurrent chemoradiation, according to a presentation at the 2016 ASCO Annual Meeting.
Chemotherapy, with or without cranial irradiation, has been associated with improved survival versus surgery alone for patients with early-stage small-cell lung cancer (SCLC) undergoing resection.
Chemotherapy use associated with a survival benefit for Medicare patients with small cell lung cancer (SCLC) treated in a real-world setting.
Chemotherapy can improve median survival by more than 6 months in elderly persons with small cell lung cancer (SCLC), a retrospective cohort study has indicated.
A histology-expression predictor has been developed for the most common types of lung cancer and can corroborate the findings of pathologists.
Persons with limited-stage small cell lung cancer (LS-SCLC) exhibited better disease control and survival when staged with positron emission tomography (PET) than did patients who did not undergo staging with PET.
Denosumab improved overall survival in persons with lung cancer and bone metastases more effectively than did zoledronic acid.
An analysis of breath samples from patients with pulmonary nodules distinguished benign from malignant growths in a recent study.
PARP1 and EZH2 may be treatment targets in small cell lung cancer, based on newfound differences between this and non-small cell disease.
Small cell lung cancers have high expression of PARP1; are more sensitive to PARP inhibition.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|